59781-11-2

Usage

Uses

Used in Pharmaceutical Industry:
[5-(benzyloxy)pyridin-2-yl]methanol is used as a building block in the synthesis of various pharmaceuticals for its versatile chemical structure and potential biological activities. Its ability to be incorporated into complex molecules makes it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, [5-(benzyloxy)pyridin-2-yl]methanol is utilized as a starting material or intermediate in the synthesis of agrochemicals, contributing to the development of effective pesticides, herbicides, and other crop protection products.
Used in Organic Synthesis:
[5-(benzyloxy)pyridin-2-yl]methanol is employed as a key intermediate in organic synthesis, allowing for the creation of a wide range of organic compounds with various applications across different industries.
Used in Medicinal Chemistry Research:
[5-(benzyloxy)pyridin-2-yl]methanol is used in medicinal chemistry research as a probe for studying the interactions between biological targets and potential drug candidates, as well as for understanding the structure-activity relationships of various pharmacologically active molecules.
Used in the Synthesis of Fine Chemicals:
[5-(benzyloxy)pyridin-2-yl]methanol is utilized in the synthesis of fine chemicals, which are high-purity chemicals used in various applications such as fragrances, flavors, dyes, and other specialty applications where high purity and specific functional groups are required.

Upstream product

• 59781-10-1 2-acetoxymethyl-5-benzyloxy pyridine 
• 63793-98-6 5-benzyloxy-2-methyl-pyridine 
• 407-25-0 trifluoroacetic anhydride 
• 100-39-0 benzyl bromide 
• 1121-78-4 5-Hydroxy-2-methylpyridine 
• 59781-09-8 5-(benzyloxy)-2-methylpyridine 1-oxide 

Downstream Products

• 648415-02-5 [1-(5-Benzyloxy-pyridin-2-yl)-meth-(E)-ylidene]-trimethylsilanyl-amine 
• 647840-12-8 (3R,4S)-4-(5-benzyloxy-2-pyridyl)-3-triisopropylsilyloxy-2-azetidinone 
• 647840-13-9 (3R,4S)-4-(5-benzyloxy-2-pyridyl)-1-(tert-butoxycarbonyl)-3-triisopropylsilyloxy-2-azetidinone 
• 647840-15-1 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-hydroxypropionate 
• 647840-16-2 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-(morpholino)ethylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-hydroxypropionate 
• 647840-14-0 (1S,2S,3R,4S,5R,8R,9S,10R,13S)-4-acetoxy-2-benzoyloxy-5,20-epoxy-1-hydroxy-9,10-[(1S)-2-propenylidenedioxy]tax-11-en-13-yl (2R,3S)-3-(5-benzyloxy-2-pyridyl)-3-(tert-butoxycarbonylamino)-2-triisopropylsilyloxypropionate 
• 886980-65-0 5-(benzyloxy)-2-(methoxymethyl)pyridine 
• 859538-90-2 5-hydroxy-2-(methoxymethyl)pyridine 
• 1612163-89-9 (E)-2-(2-(5-(benzyloxy)pyridin-2-yl)vinyl)-5,8-dimethyl-[1,2,4]triazolo[1,5-a]pyrazine 
• 1408443-52-6 di-tert-butyl (4R)-N-(tert-butoxycarbonyl)-4-{[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)-1-oxidopyridin-2-yl]methyl}-L-glutamate 
• 1408443-30-0 di-tert-butyl (2S)-2-[(tert-butoxycarbonyl)amino]-5-{[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-2-yl]methyl}hexanedioate 
• 1408443-19-5 di-tert-butyl (4R)-N-(tert-butoxycarbonyl)-4-{[5-(2-{[(4-methylphenyl)sulfonyl]oxy}ethoxy)pyridin-2-yl]methyl}-L-glutamate 
• 1204424-83-8 5-(benzyloxy)-2-(bromomethyl)pyridine 
• 1407507-36-1 di-tert-butyl (4R)-4-{[5-(benzyloxy)pyridin-2-yl]methyl}-N-(tert-butoxycarbonyl)-L-glutamate 

Relevant academic research and scientific papers

Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation

Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe

TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.

Inhibition of 1-deoxy-d-xylulose-5-phosphate reductoisomerase by lipophilic phosphonates: SAR, QSAR, and crystallographic studies

1-Deoxy-d-xylulose-5-phosphate reductoisomerase (DXR) is a novel target for developing new antibacterial (including antituberculosis) and antimalaria drugs. Forty-one lipophilic phosphonates, representing a new class of DXR inhibitors, were synthesized, among which 5-phenylpyridin-2-ylmethylphosphonic acid possesses the most activity against E. coli DXR (EcDXR) with a K i of 420 nM. Structure-activity relationships (SAR) are discussed, which can be rationalized using our EcDXR:inhibitor structures, and a predictive quantitative SAR (QSAR) model is also developed. Since inhibition studies of DXR from Mycobacterium tuberculosis (MtDXR) have not been performed well, 48 EcDXR inhibitors with a broad chemical diversity were found, however, to generally exhibit considerably reduced activity against MtDXR. The crystal structure of a MtDXR:inhibitor complex reveals the flexible loop containing the residues 198-208 has no strong interactions with the 3,4-dichlorophenyl group of the inhibitor, representing a structural basis for the reduced activity. Overall, these results provide implications in the future design and development of potent DXR inhibitors.

NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND

The present invention provides a compound having excellent regulating action on blood lipid level. The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH or the like; each R2 represents an alkyl or the like; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl, or the like; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl, or the like; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.

OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE

The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE

Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): (wherein X1 to X4 represent a carbon atom, etc., ring A represents a 5- or 6-membered heteroaryl having from 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, X5 represent an oxygen atom, etc., X represent a carbon atom, etc., Het represents a 5- or 6-membered aliphatic hetero ring, R1 represents aryl, etc., R2 represents formyl, etc., R3 represents -C1-6 alkyl, etc.), as well as their pharmaceutically acceptable salts.

QUINAZOLINE DERIVATIVES

The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

First chiral synthesis of the N-terminal amino acid congener of nikkomycin Z based on lipase-catalyzed enantioselective acetylation of a primary alcohol possessing two stereogenic centers

A stereoselective synthesis of a versatile chiral synthon possessing two stereogenic centers, (2S,3S)-3-[2-(5-benzyloxypyridyl)]-2-methyl-1,3-propane diol 12 (>99% ee), was achieved by using a chemo-enzymatic method. The conversion of (2S,3S)-12 to the ho

Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents

A series of novel pyridine-2-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARα/γ agonists with varied isoform selectivity. Based on the results of efficacy studies in